SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 47 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $402,000 | -20.6% | 28,800 | -22.0% | 0.01% | -22.2% |
| Q1 2017 | $506,000 | +90.9% | 36,900 | 0.0% | 0.01% | +80.0% |
| Q4 2016 | $265,000 | -52.6% | 36,900 | 0.0% | 0.01% | -50.0% |
| Q3 2016 | $559,000 | +24.8% | 36,900 | -18.9% | 0.01% | +25.0% |
| Q2 2016 | $448,000 | -15.9% | 45,500 | +13.8% | 0.01% | -11.1% |
| Q1 2016 | $533,000 | – | 40,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |